WeVote
Log In

Bill

Bill

HB 79

State Board of Pharmacy and Employers, prohibited from disciplining pharmacists who recommend off-label medical treatments

2025 Regular Session Introduced by Chip Brown

Alabama bill shields pharmacists from discipline for recommending FDA-approved drugs for non-approved medical uses, expanding treatment options but potentially limiting regulatory oversight.

Reported Out of Committee Second House
#occupationallicensingboards
0
WeVote Research Nonpartisan
Bill Summary · HB 79

Legislative bill overview

HB 79 prohibits the Alabama State Board of Pharmacy and employers from disciplining pharmacists who recommend off-label medical treatments to patients. The bill protects pharmacists from professional sanctions or employment termination based solely on recommending FDA-approved medications for uses not explicitly approved by the agency.

Why is this important

This bill directly affects patient access to treatment options and pharmacist professional autonomy. Off-label prescribing is a common medical practice—an estimated 20% of prescriptions are written off-label—but pharmacist recommendations about such uses currently operate in a gray regulatory area. The bill's passage would significantly reshape the professional liability landscape for pharmacy practice in Alabama.

Potential points of contention

  • Patient safety concerns: Critics may argue that limiting disciplinary authority could allow pharmacists to recommend treatments without sufficient evidence, potentially endangering patients who lack direct physician guidance
  • Regulatory authority erosion: Medical and pharmacy boards traditionally maintain disciplinary power to enforce standards of care; this bill removes a key enforcement mechanism
  • Undefined standards: The bill doesn't specify what constitutes a reasonable or evidence-based off-label recommendation, creating ambiguity about when recommendations cross into negligence
  • Insurance and liability implications: Unclear how this interacts with malpractice insurance, employer policies, and liability for adverse outcomes from off-label recommendations

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.